

1 **Peripheral arteriopathy caused by Notch3 gain-of-function mutation is**
2 **associated with increased Ca²⁺ and redox signaling and blunting of**
3 **NO/sGC/cGMP pathway**

4
5 *Karla B Neves, PhD¹; Hannah Morris, MSc¹; Rhéure Alves-Lopes, PhD¹; Keith W
6 Muir, MD, PhD²; Fiona Moreton, MD, PhD²; Christian Delles, MD, PhD¹; Augusto C
7 Montezano, PhD¹; *Rhian M Touyz, MD, PhD¹.

8
9
10 ¹Institute of Cardiovascular and Medical Sciences, University of Glasgow, UK;

11 ²Institute of Neuroscience & Psychology, University of Glasgow and Queen Elizabeth
12 University Hospital.

13
14 **Short title:** Peripheral arteriopathy and CADASIL

15 **Category of Manuscript:** Original Article

16
17
18
19 **To whom correspondence should be addressed:**

20 *Karla B Neves PhD and Rhian M Touyz MD, PhD

21 Institute of Cardiovascular and Medical Sciences,

22 University of Glasgow,

23 126 University Place, Glasgow, G12 8TA,

24 Glasgow, UK

25 Phone: + 44 (0)141 330 7775/7774,

26 Fax: + 44 (0)141 330 3360,

27 Email: Karla.Neves@glasgow.ac.uk; Rhian.Touyz@glasgow.ac.uk

28

29 **Abstract**

30 Notch3 mutations cause Cerebral Autosomal Dominant Arteriopathy with Subcortical
31 Infarcts and Leukoencephalopathy (CADASIL), which predisposes to stroke and
32 dementia. CADASIL is characterized by vascular dysfunction and granular osmiophilic
33 material (GOM) accumulation in cerebral small vessels. Systemic vessels may also
34 be impacted by Notch3 mutations. However vascular characteristics and
35 pathophysiological processes remain elusive. We investigated mechanisms
36 underlying the peripheral vasculopathy mediated by CADASIL-causing Notch3 gain-
37 of-function mutation. We studied: i) small arteries and vascular smooth muscle cells
38 (VSMC) from TgNotch3^{R169C} mice (CADASIL model), ii) VSMCs from peripheral
39 arteries from CADASIL patients, and iii) post-mortem brains from CADASIL individuals.
40 TgNotch3^{R169C} vessels exhibited GOM deposits, increased vasoreactivity and
41 impaired vasorelaxation. Hypercontractile responses were normalized by fasudil (Rho
42 kinase inhibitor) and 4-PBA (endoplasmic-reticulum (ER) stress inhibitor). Ca²⁺
43 transients and Ca²⁺ channel expression were increased in CADASIL VSMCs, with
44 increased expression of Rho GEFs and ER stress proteins. Vasorelaxation
45 mechanisms were impaired in CADASIL, evidenced by decreased eNOS
46 phosphorylation and reduced cGMP levels, with associated increased guanylate
47 cyclase (sGC) oxidation, decreased sGC activity and reduced levels of the vasodilator
48 H₂O₂. In VSMCs from CADASIL patients, sGC oxidation was increased and cGMP
49 levels decreased, effects normalized by fasudil and 4-PBA. Cerebral vessels in
50 CADASIL patients exhibited significant oxidative damage. In conclusion, peripheral
51 vascular dysfunction in CADASIL is associated with altered Ca²⁺ homeostasis,
52 oxidative stress and blunted eNOS/sGC/cGMP signaling, processes involving Rho
53 kinase and ER stress. We identify novel pathways underlying the peripheral

54 arteriopathy induced by Notch3 gain-of-function mutation, phenomena that may also
55 be important in cerebral vessels.

56

57 **Key words:** Notch3, small arteries, vascular signalling, oxidation, vascular dementia.

58

59 **Introduction**

60 Notch proteins are cell membrane receptors that play a crucial role in cell-to-cell
61 communication [1]. In mammals four Notch receptors and five ligands have been
62 identified and although they share the same primary structure, Notch receptors are
63 expressed in a cell-specific manner and mediate diverse cellular effects [2, 3]. Notch
64 signalling induces transcription of target genes that influence cell differentiation,
65 maturation, proliferation and apoptosis and is critically involved in the regulation of
66 vascular smooth muscle cell (VSMC) function [4, 5]. In the vasculature, of the Notch
67 receptor family, Notch3 is expressed predominantly in VSMCs, where it controls
68 maintenance of cell phenotype and growth [5, 6]. Abnormal Notch3 signalling has been
69 implicated in cardiovascular diseases associated with excessive VSMC proliferation
70 and vascular remodeling such as pulmonary arterial hypertension [4].

71 Mutations of Notch3 are responsible for the monogenic inherited cerebral
72 arteriopathy known as Cerebral Autosomal Dominant Arteriopathy with Subcortical
73 Infarctions and Leukoencephalopathy (CADASIL) that leads to premature stroke and
74 vascular dementia [7]. Progressive degeneration of VSMCs, accumulation of
75 abnormal protein (granular osmiophilic material (GOM)) around VSMCs, and
76 cerebrovascular dysfunction are characteristic features of CADASIL [7, 8]. In the brain,
77 these processes present as subcortical lacunes and white matter rarefaction due to

78 chronic ischaemia, and manifest clinically as premature stroke, mood and behaviour
79 disturbances, cognitive decline, migraines and dementia [9-11].

80 Investigations of the pathogenesis and molecular mechanisms of CADASIL
81 have been performed in large part using experimental models of CADASIL and
82 cultured patient-derived VSMCs and induced pluripotent stem cells [12-14]. We
83 recently demonstrated that isolated small peripheral arteries from CADASIL patients
84 exhibit vascular dysfunction and structural remodelling with associated VSMC
85 oxidative and endoplasmic reticulum (ER) stress and altered Rho kinase signalling
86 (12). Proteomic analysis in VSMCs from a CADASIL patient showed increased
87 expression of proteins involved in protein degradation/folding, cytoskeletal
88 organisation, contraction and cell stress [15].

89 Vascular remodeling in CADASIL mice is related to increased deposition of
90 extracellular matrix (ECM) proteins [14, 16, 17], VSMC proliferation and cellular
91 mitochondrial dysfunction [12, 18-20]. Studies in a CADASIL mouse model,
92 TgNotch3^{R169C} mice, demonstrated cerebrovascular dysfunction and thickening, with
93 associated increased deposition of extracellular matrix proteins, upregulation of
94 voltage-dependent potassium (Kv1) channels, blunted membrane depolarization and
95 reduced myogenic tone [14, 21].

96 Although the genetic cause of CADASIL is known and the clinical features of
97 CADASIL are well defined, understanding the molecular and cellular processes
98 underlying the vasculopathy induced by the Notch3 mutations still remain incompletely
99 understood. This is attributed to the wide genetic diversity of Notch3 mutations, but
100 also to the incomplete understanding of Notch3 function in blood vessels. Our previous
101 findings identified important interplay between vascular Notch3, ER stress and Rho
102 kinase, in part through Nox5-derived reactive oxygen species (ROS), in CADASIL

103 patients [12]. Here we have further interrogated molecular and cellular mechanisms
104 whereby a Notch3 gain-of-function mutation alters vascular function of peripheral small
105 arteries, using a mouse model harbouring one of more than 200 distinct Notch3
106 mutations already described as associated with CADASIL [22].

107

108 **Methods**

109 **Study approval**

110 Ethics approval for the use of human blood vessel samples was obtained from the
111 West of Scotland Research Ethics Service (WS/12/0294). Written informed consent
112 was obtained for all study participants in accordance with the Declaration of Helsinki.
113 Human brain samples were from biobanked tissue from NHSGGC Biorepository and
114 Pathology Service Tissue Resource. Ethical approval for use of surplus tissue from
115 diagnostic blocks was obtained (REC 16/WS/0207). Experiments were approved by
116 the University of Glasgow Animal Welfare and Ethics Review Board. All experimental
117 protocols on mice were performed in accordance with the United Kingdom Animals
118 Scientific Procedures Act 1986 (Licence No. 70/9021) and with ARRIVE Guidelines.
119 All animal studies have taken place at the University of Glasgow, UK.

120 **Subject recruitment**

121 Patients with genetically confirmed CADASIL were recruited from the Neurovascular
122 Genetics clinic, Queen Elizabeth University Hospital, Glasgow. Healthy controls were
123 volunteers at the hospital. Under local anaesthetic, all subjects underwent a gluteal
124 biopsy from which intact small arteries (<400 μm diameter) were dissected from
125 subcutaneous fat. VSMCs were isolated for primary cell culture, as previously
126 described [23, 24] and summarized below. Identical protocols were used for CADASIL
127 patients and control studies.

128 **Human brain samples from patients with CADASIL**

129 Human brain samples were from biobanked tissue from NHSGGC Biorepository and
130 Pathology Service Tissue Resource. At routine diagnostic autopsy, whole brains were
131 immersion fixed in 10% formal saline for a minimum of 2 weeks prior to dissection,
132 standardized anatomical sampling, tissue processing and embedding in paraffin as
133 previously described [25]. From diagnostic blocks, sections of 5 μ m were dissected.
134 Samples where blood vessels were visible were chosen. We studied four brains from
135 CADASIL patients and three brains from individuals who had died from various causes
136 (Supplemental Table 1).

137 **Mouse model of CADASIL**

138 The transgenic (Tg) mouse lines, TgNotch3^{WT} and TgNotch3^{R169C}, have been
139 previously characterized and described. Briefly, TgNotch3^{WT} and TgNotch3^{R169C} mice
140 (on an FVB background) express rat wild-type Notch3 and the CADASIL-causing
141 Notch3(R169C) mutant protein, respectively, to a similar degree (approximately four-
142 fold) compared with levels of endogenous Notch3 in non-transgenic mice [22]. The
143 transgene is integrated on the X chromosome, and random inactivation of 1 X
144 chromosome in females results in mosaic expression of the mutant protein in
145 TgNotch3^{R169C} female mice (Unpublished data). Therefore, only male mice were used
146 in this study. Mice were housed in individual cages in a room with controlled humidity
147 and temperature (22°C - 24°C), and in light/dark cycles of 12 hours with free access to
148 food and tap water. They were studied at 24 weeks of age, at which stage features
149 consistent with CADASIL are well established and they exhibit features of the human
150 disease, as previously described [14, 16, 21, 22, 26]. For each set of experiments, we
151 used five to eight different mice. Mice were anaesthetized with 5% isoflurane (1.5
152 L/min O₂) for blood collection via cardiac puncture, which is a terminal procedure, and

153 tissues were collected for future experiments. For each set of experiments, we used
154 five to eight different mice. Blood and tissues were collected for experiments. Small
155 mesenteric arteries were used to assess vascular function and molecular studies. In
156 previous study we demonstrated that this is a gain-of-function mutation, where
157 increased Notch3 signalling is observed in VSMCs and arteries. Body weight and
158 systolic blood pressure of TgNotch3^{R169C} mice were similar to wild-type (TgNotch3^{WT})
159 controls. Cardiac function and structure were similar between groups. Clinical features
160 of subjects and mice phenotype were also shown previously [12].

161 **Transmission Electron Microscopy (TEM)**

162 GOM deposition in mesenteric arteries from TgNotch3^{WT} and TgNotch3^{R169C} mice was
163 examined by transmission electron microscopy. Arteries (2 mm thick slices) were fixed
164 in 2% Glutaraldehyde / 2% Paraformaldehyde / 0.1M Sodium Cacodylate buffer
165 overnight at 4°C and rinsed with 0.1M Sodium Cacodylate buffer three times of 5
166 minutes before post fixation in 1% Osmium Tetroxide for 1 hour. Osmium Tetroxide
167 was removed with changes of distilled H₂O (dH₂O) three times of 10 minutes each.
168 Samples were then stained with 0.5% Uranyl Acetate / dH₂O for 1 hour in the dark
169 prior dehydration through an ethanol series of 30, 50, 70, 90% (15 minutes each),
170 100% ethanol (4 times of 5 minutes), dried 100% ethanol (plus 3A Molecular sieve) (4
171 times of 5 minutes), followed by three times changes of Propylene Oxide for 5 minutes
172 each. Samples were then placed into a mix of Propylene Oxide: EPON 812 resin 1:1
173 pure resin overnight, fresh resin embedded next day in moulds and polymerised at
174 60°C for 48 hours. Ultrathin sections (50-70 nm) were cut using a DRUKKER diamond
175 ultratome Knife and a LEICA Ultracut UTC. Sections were collected on Formvar
176 coated 100 mesh copper grids and contrast was stained with 2% Uranyl Acetate for 5
177 minutes and Reynolds Lead Citrate also for 5 minutes. Tissue samples were viewed

178 on a JEOL 1200EX TEM running at 80kv and digital images captured using a Cantega
179 2K X 2K camera and Olympus ITEM software.

180 **Vascular functional studies**

181 Mouse mesenteric resistance arteries (first and second order; ~300-350 μm) were
182 isolated from TgNotch3^{WT} and TgNotch3^{R169C} mice. Briefly, arterial segments were
183 mounted on isometric wire myographs (Danish Myo Technology, Denmark) filled with
184 5ml of physiological saline solution [(in mmol/L: 130 NaCl, 14.9 NaHCO₃, 4.7 KCl,
185 1.18KH₂PO₄, 1.17 MgSO₄·7H₂O, 5.5 glucose, 1.56 CaCl₂·2H₂O, and 0.026 EDTA] and
186 continuously gassed with a mixture of 95% O₂ and 5% CO₂ while being maintained at
187 a constant temperature of 37±0.5°C. Following 30 minutes of equilibration, the
188 contractile responses of arterial segments were assessed by the addition of KCl
189 (62.5mmol/L). The integrity of the endothelium was verified by relaxation induced by
190 acetylcholine (ACh) (3x10⁻⁶ mol/L) in arteries pre-contracted with thromboxane A2
191 agonist (U46619) (3x10⁻⁸ mol/L). Endothelium-dependent relaxation was assessed as
192 a dose-response to acetylcholine (ACh, 10⁻⁹-10⁻⁵ mol/L). Endothelium-independent
193 vasorelaxation was assessed by a dose-response to sodium nitroprusside (SNP) (10⁻
194 ¹⁰ – 10⁻⁵ mol/L), BAY 58-2667 (10⁻¹² – 10⁻⁵ mol/L) and 8-Bromoguanosine 3',5'-cyclic
195 monophosphate sodium salt (8-Br-cGMP) (10⁻⁸ – 10⁻⁴ mol/L). Concentration-response
196 curves to phenylephrine (Phe) (10⁻⁹ – 3x10⁻⁵ mol/L), U46619 (10⁻¹⁰ – 10⁻⁶ mol/L) and
197 angiotensin II (Ang II) (10⁻¹⁰ – 3x10⁻⁵ mol/L) were performed to evaluate
198 vasoconstriction. Vascular functional responses were also assessed in the absence
199 and presence of 4-Phenylbutyric acid (4-PBA) (ER stress inhibitor; 1 mmol/L, 30
200 minutes) or fasudil (Rho Kinase inhibitor; 1 $\mu\text{mol/L}$, 30 minutes).

201 **Vascular smooth muscle cell isolation**

202 Methods for the isolation and culture of human VSMCs (from isolated small arteries
203 from gluteal biopsies) and mice (from mesenteric arteries) have been previously
204 described [24]. Briefly, cleaned arteries were placed in Ham's F-12 culture medium
205 containing 1% gentamicin, collagenase (type 1), elastase, soybean trypsin inhibitor
206 and BSA, and were incubated for 30 to 60 minutes at 37°C under constant agitation.
207 The digested tissue was further dissociated by repeated aspiration through a syringe
208 with 20G needle. The cell suspension was centrifuged (2000 rpm, 4 minutes) and the
209 cell pellet was resuspended in Ham's F-12 culture medium containing 10% FBS. Cells
210 were seeded onto 25mm flask. VSMCs were maintained in DMEM media
211 supplemented with 10% fetal bovine serum (FBS) and Penicillin/Streptomycin (50
212 µg/ml). Before experimentation, cells were rendered quiescent by maintenance in a
213 reduced growth supplement medium (0.5% FBS) overnight. Only primary, low
214 passage cells (passages 4 to 8) were studied. In some protocols, the role of ER stress,
215 Rho kinase and Notch signalling was assessed using pharmacological inhibitors: ER
216 stress inhibitor, 4-phenylbutyrate (4-PBA, 1 mmol/L, Sigma-Aldrich, UK) and Rho
217 kinase inhibitor, fasudil (10 µmol/L, Tocris, UK). Cells were pre-exposed to 4-PBA and
218 fasudil for 24 hours.

219 **Quantitative real-time Polymerase Chain Reaction**

220 Quantitative real-time Polymerase Chain Reaction (qPCR) (Qiagen, UK) was used to
221 assess mRNA expression in TgNotch3^{WT} and TgNotch3^{R169C} mice VSMCs and
222 mesenteric arteries. For some experiments, wildtype FVB mice were used as a control
223 for Notch3 and Notch3 target gene expression since TgNotch3^{WT} and TgNotch3^{R169C}
224 mice were on a FVB background. Briefly, total RNA was extracted from tissues using
225 TRIzol (Qiagen, Manchester, UK), treated with RNase-free DNase I, and 2 µg of RNA
226 was reverse transcribed in a reaction containing 100 µg/mL oligo-dT, 10 mmol/L of 2'-

227 deoxynucleoside 5'-triphosphate, 5×first-Strand buffer, and 2 µL of 200-U reverse
228 transcriptase. For real-time PCR amplification, 3 µL of each reverse transcription
229 product were diluted in a reaction buffer containing 5 µL of SYBR Green PCR master
230 mix and 300 nmol/L of primers in a final volume of 10 µL per sample. The reaction
231 conditions consisted of 2 steps at 50°C for 2 minutes and 95°C for 2 minutes, followed
232 by 40 cycles of 3 steps, 15-second denaturation at 95°C, 60-second annealing at
233 60°C, and 15 seconds at 72°C. Mouse primers used are detailed in supplementary
234 table S2. Data are expressed as target gene/GAPDH housekeeping gene. Relative
235 gene expression was calculated using the $2^{\Delta\Delta C_t}$ method.

236 **Measurement of intracellular Ca²⁺ transients in VSMCs**

237 VSMC Ca²⁺ signalling was assessed using the fluorescent Ca²⁺ indicator, Cal-520
238 acetoxymethyl ester (Cal-520/AM; Abcam; 10 µmol/L). Cells were grown in 12-well
239 plates and following removal of culture media were incubated with Cal-520 AM in 0.5%
240 FBS at 37°C for 75 minutes followed by 30 minutes at room temperature. Following
241 incubation, the dye solution was replaced with HEPES physiological saline solution
242 (1.3x10⁻¹ mol/L NaCl, 5x10⁻³ mol/L KCl, 10⁻³ mol/L CaCl, 10⁻³ mol/L MgCl, 2x10⁻² mol/L
243 HEPES, and 10⁻² mol/L D-glucose, pH 7.4) for 30 minutes prior to imaging.
244 Fluorescence intensity as a measure of [Ca²⁺]_i, was monitored for 30 seconds in basal
245 condition and 180 minutes under U46619 (1 µmol/L) stimulation. In some experiments,
246 VSMCs were pre-treated for 24 hours with 4-PBA. Fluorescence-based
247 measurements of Ca²⁺ signals were performed using an inverted epifluorescence
248 microscope (Axio Observer Z1 Live-Cell imaging system; Zeiss, Cambridge, UK) with
249 excitation/emission wavelengths 490/535nm, respectively. Images were acquired and
250 analysed using Zen Blue Program (Zeiss, Cambridge, UK).

251 **Immunoblotting**

252 Protein was extracted from mesenteric arteries isolated from TgNotch3^{WT} and
253 TgNotch3^{R169C} mice. Protein (30µg) was separated by electrophoresis on a
254 polyacrylamide gel and transferred to a nitrocellulose membrane. Non-specific binding
255 sites were blocked with 3% bovine serum albumin in Tris-buffered saline (TBS)
256 solution. Membranes were then incubated with specific antibodies overnight at 4°C.
257 Membranes were washed 3 times with TBS-Tween20 and incubated with infrared dye-
258 labelled secondary antibodies for 1 hour at room temperature. Membranes were
259 visualized using an Odyssey CLx infrared imaging system (LiCor Biosciences UK Ltd,
260 UK) and results were normalized to β-actin protein and are expressed in arbitrary units
261 compared to wildtype group, which was taken as 100. Antibodies used were as
262 follows: anti-β-actin (1:5000; Sigma-Aldrich, UK); anti-phospho-eNOS^{Thr495} (1:500;
263 Santa Cruz, UK); anti-phospho-eNOS^{Ser1177} (1:1000; Cell signalling, UK); anti-total-
264 eNOS (1:1000; Cell signalling, UK) anti-sGCβ1 (1:500; Cayman Chemical, UK), anti-
265 ERO1 (1:1000; Santa Cruz, UK).

266 **Affinity capture of sulfenylated proteins**

267 Sulfenylated proteins were captured using a biotin-tagged dimedone-based probe
268 (DCP-Bio, Merck NS1226-5MG) that specifically binds sulfenic acid groups (SOH) in
269 proteins [27]. Mesenteric arteries from FVB, TgNotch3^{WT} and TgNotch3^{R169C} mice and
270 VSMC isolated from control and CADASIL patients, after homogenization in lysis
271 buffer were supplemented with DCP-Bio1 (1mM), N-methylmaleimide (10mM),
272 catalase (200U) and protease inhibitors (1mM PMSF and 1 µg/mL of aprotinin,
273 leupeptin and pepstatin). Samples were kept on ice for 30 minutes and centrifuged at
274 12,000g for 4 minutes at 4°C. Supernatants were collected and DCP-Bio1 excess was
275 removed by acetone precipitation. The pellet was washed in 70% acetone and
276 suspended in non-supplemented lysis buffer. Protein levels were determined, and 300

277 μg of total protein was added to a 50 μl slurry of non-liganded support beads
278 (sepharose CL-4B beads, Sigma-Aldrich, Seelze, Germany) to remove proteins with
279 a tendency to bind non-specifically and incubated for 2 hours at 4°C with constant
280 rotation. Beads were centrifuged at 1,000 x g for 2 minutes. The supernatant was
281 collected and incubated with streptavidin beads (High Capacity Streptavidin–Agarose
282 Resin, Thermo Scientific, Illinois, USA) overnight at 4°C with constant rotation. After
283 the incubation steps beads were centrifuged at 1,000 x g for 2 minutes and washed
284 with PBS three times. Proteins were then eluted in 50 μl of 2x sample buffer for western
285 blotting and boiled at 95°C for 5 min. As a procedural control for the affinity capture, it
286 was used Biotinylated-Trx Loading Control Protein (Kerafast EE0035). In order to
287 concentrate the proteins for the protocol, a pool of five samples from different mice or
288 patients was made.

289 **Immunofluorescence**

290 Immune staining was performed for an endoplasmic reticulum (ER) stress regulator,
291 BiP, and 8-Hydroxyguanosine (8-OHG), an indirect oxidative stress marker. 8-OHG is
292 a modified guanosine that occurs in DNA/RNA due to attack by hydroxyl radicals that
293 are formed as by products and intermediates of aerobic metabolism and during
294 oxidative stress. 8-OHG immunohistochemistry has been widely used as a sensitive,
295 stable and integral biomarker of oxidative stress-induced DNA and RNA damage [28].
296 GRP78/BiP is a major ER chaperone protein critical for protein quality control of the
297 ER, regulating ER stress-signalling pathways leading to unfolded protein responses
298 (UPR) survival and apoptosis responses [29]. Paraffin sections (5 μm) of brain from
299 control and CADASIL patients and mesenteric arteries from TgNotch3^{WT} and
300 TgNotch3^{R169C} mice were deparaffinized in xylene, rehydrated through graded ethanol,
301 and washed in water. All sections were incubated in EDTA (pH 8.0) and boiled for 15

302 minutes at 95°C for antigen unmasking. Slides were cooled to room temperature,
303 permeabilized in 0.5% Triton X-100 in phosphate-buffered saline (PBS) for 5 minutes,
304 and blocked with 10% donkey serum, 1% bovine serum albumin (BSA) in 1x Tris-
305 buffered saline and Tween 20 (TBS-T) for 1 hour at room temperature in a humidified
306 chamber. For 8-OHG immunostaining, slides were incubated overnight with anti- 8-
307 OHG goat polyclonal antibody (Abcam ab10802, 1:200 diluted in 5% donkey serum,
308 0.02% BSA, 0.0025% Tween-20 in 1x TBS solution) in a humidified chamber; and
309 Alexa-fluor-488-conjugated donkey anti-goat antibody (Molecular probes, A-11055,
310 1:300 dilution in 5% donkey, 0.02% BSA, 0.0025% Tween-20 in 1xTBS solution) was
311 used as secondary antibody. For BiP immunostaining, slides were incubated overnight
312 with anti-BiP rabbit antibody (Cell 3177, 1:200 diluted in 5% donkey serum, 0.02%
313 BSA, 0.0025% Tween-20 in 1x TBS solution) in a humidified chamber, and Alexa-
314 fluor-488-conjugated donkey anti-rabbit (Molecular probes, A-11034, 1:300 dilution in
315 5% donkey, 0.02% BSA, 0.0025% Tween-20 in 1xTBS solution) secondary antibody
316 was used. For both staining, after primary antibody incubation, secondary antibodies
317 were incubated for 1 hour at room temperature in the dark. Slides were treated with
318 0.1% Sudan Black B (Sigma Aldrich, 199664) in methanol for 10 minutes to minimise
319 autofluorescence. Sections were mounted with a coverslip using ProLong Gold anti-
320 fade mounting media containing DAPI (Molecular probes, P-36931) at room
321 temperature and then stored at 4°C in the dark. Fluorescence images were captured
322 at 20X (brain vessels from patients) or 63X (mesenteric arteries from mice)
323 magnification using an inverted epifluorescence microscope (Axio Observer Z1, Zeiss)
324 and a dedicated software (Zen Blue Program, Zeiss). Laser excitation and acquisition
325 settings were maintained constant across all slides. Image analyses were performed

326 using the software ImageJ[®], where a mean of the green fluorescence intensity from at
327 least 3 vessels from each mice or patient was taken.

328 **cGMP ELISA**

329 Cyclic guanosine 3',5'-monophosphate (cGMP) levels were detected in this study in
330 VSMC isolated from TgNotch3^{WT} and TgNotch3^{R169C} mice and control and CADASIL
331 patients by ELISA assay according the manufacturer's protocol (Cyclic GMP Assay
332 kit, Cell Signaling Technology). Results were normalized by concentration of protein.

333 **Lucigenin-enhanced chemiluminescence**

334 Lucigenin-derived chemiluminescence assay was used to determine NADPH-
335 dependent ROS production in mesenteric arteries homogenates from TgNotch3^{WT} and
336 TgNotch3^{R169C} mice as we previously described [30]. Briefly, tissues were
337 homogenized in lysis buffer (20 mmol/L of KH₂PO₄, 1 mmol/L of EGTA, 1 µg/mL of
338 aprotinin, 1 µg/mL of leupeptin, 1 µg/mL of pepstatin, and 1 mmol/L of PMSF). 50 µl
339 of the sample were added to a suspension containing 175 µl of assay buffer (50
340 mmol/L of KH₂PO₄, 1 mmol/L of EGTA, and 150 mmol/L of sucrose) and lucigenin (5
341 µmol/L). Luminescence was measured with a luminometer (AutoLumat LB 953,
342 Berthold) before and after stimulation with nicotinamide adenine dinucleotide
343 phosphate (NADPH, 100 µmol/l). A buffer blank was subtracted from each reading.
344 Results were normalized by concentration of protein, as measured by the BCA assay.

345 **Amplex Red assay**

346 Hydrogen peroxide (H₂O₂) levels was assessed by Amplex red[®] assay in mesenteric
347 arteries from TgNotch3^{WT} and TgNotch3^{R169C} mice. Protocols were made according to
348 the manufacture's instruction using the horseradish peroxidase-linked Amplex Red
349 fluorescence assay (A22188; Life Technologies). Fluorescence readings were made

350 in a 96-well plate at Ex/Em = 530/590 nm. H₂O₂ production was normalized to protein
351 concentration.

352 **Plasma TBARS measurement**

353 Thiobarbituric acid reactive substances (TBARS) are a well-established indicator of
354 oxidative stress in cells, plasma and tissues. Its products were detected in this study
355 in plasma from TgNotch3^{WT} and TgNotch3^{R169C} mice by colorimetric (532-535nm)
356 assay according the manufacturer's protocol (Cayman's TBARS Assay Kit, Cayman
357 Chemical - CAY700870).

358 **Statistical analysis**

359 For vascular functional studies, concentration-response curves were generated and
360 the maximal effect (E_{max}) and the agonist concentration that produced 50% of the
361 maximal response (log EC₅₀) were calculated using nonlinear regression analysis.
362 pD₂ (defined as the negative logarithm of the EC₅₀ values) and E_{max} were compared
363 by Student's *t*-test or two-way analysis of variance (ANOVA) with Bonferroni post-test,
364 as appropriate. For the other experiments, statistical comparisons between groups
365 were performed using two-tailed student's *t*-test and or one-way ANOVA. Bonferroni
366 or Dunnett post-test were used as appropriate. p<0.05 was considered statistically
367 significant. Data analysis was conducted using GraphPad Prism[®] 6.0 (GraphPad
368 Software Inc., San Diego, CA). Data are expressed as mean ± SEM.

369

370 **Results**

371 **GOM deposits in small peripheral arteries**

372 A characteristic feature of CADASIL is cerebrovascular GOM deposition [8]. GOM
373 deposits have been identified in VSMC in skin biopsies from CADASIL patients [31],
374 however whether GOM accumulates around VSMCs in peripheral small arteries is

375 unclear. As shown in figures 1A and 1B, electron microscopic analysis revealed GOM
376 deposits in mesenteric resistance arteries from TgNotch3^{R169C} mice but not in
377 TgNotch3^{WT} mice. GOM deposits were located close to the smooth muscle cells
378 (SMCs), often within an infolding of the cell membrane (Figure 1B, arrows). The
379 intercellular space between SMCs from TgNotch3^{R169C} mice is also enlarged when
380 compared to wildtype mice, which might be associated with increased deposition of
381 ECM components such as MMP2 and MMP9. Previous studies in cerebral vessels
382 from TgNotch3^{R169C} mice showed increased MMP expression [14, 21]. Here we
383 corroborate this in peripheral vessels, since mRNA expression of MMP2 and MMP9
384 was increased in CADASIL mice (Supplementary figure 2A, 2B).

385 **Altered vascular function of peripheral small arteries in CADASIL**

386 Small resistance arteries were studied by wire myography to assess vascular
387 contraction and relaxation. In small arteries from TgNotch3^{R169C} mice, contractile
388 responses to multiple vasoconstrictors including Phe, U46619 and Ang II were
389 increased compared with vessels from TgNotch3^{WT} mice (Supplementary figure 1A,
390 1B, 1C). These responses were restored when arteries were exposed to inhibitors of
391 Rho kinase (fasudil; Figures 2A, 2C, 2E) or ER stress (4-PBA; Figures 2B, 2D, 2F).
392 No changes were observed in vessels from TgNotch3^{WT} mice incubated with fasudil
393 or 4-PBA.

394 In addition to hypercontractile responses, CADASIL mice exhibited significantly
395 reduced endothelium-dependent (ACh-induced) and endothelium-independent
396 vasorelaxation (SNP-induced) compared with wildtype vessels (Figures 2G, 2H).
397 Maximum response for ACh-induced relaxation in TgNotch3^{R169C} was 73.7±3.9 versus
398 103.1±7.5 in TgNotch3^{WT} mice (p<0.05). EC₅₀ for SNP-induced vasorelaxation was
399 7.0±0.2 in TgNotch3^{R169C} versus 7.8±0.1 in wildtype mice (p<0.05). Pre-treatment of

400 vessels with 4-PBA normalized ACh-induced vasorelaxation in CADASIL mice (Figure
401 2G).

402 **Molecular mechanisms underlying vascular dysfunction in peripheral small** 403 **arteries in CADASIL**

404 To explore putative mechanisms underlying augmented vasoconstriction in CADASIL
405 vessels, we assessed some of the molecular machinery and signalling pathways that
406 control VSMC contraction. In particular we measured changes in agonist-stimulated
407 Ca^{2+} responses and Ca^{2+} channels and activation of the Rho kinase and ER stress
408 pathways in mesenteric arteries and VSMCs. As shown in figure 3, Ca^{2+} transients
409 and expression of various Ca^{2+} channels were altered in TgNotch3^{R169C}-derived
410 VSMCs, compared with wildtype VSMCs. Agonist-stimulated Ca^{2+} responses (Figure
411 3A) and the calculated area under the curve (Figure 3B) were significantly increased
412 in the TgNotch3^{R169C} group compared with control mice. Pre-treatment with 4-PBA
413 attenuated Ca^{2+} responses in CADASIL VSMCs. Gene expression of the Ca^{2+}
414 channels voltage-dependent L-type calcium channel, subunit α_{1S} (*Cav1.1*), transient
415 receptor potential cation channel, subfamily M, member 2 (*TRPM2*) and ryanodine
416 receptor 1 (*RyR1*) was augmented in TgNotch3^{R169C}-derived VSMCs, whereas no
417 changes were observed for inositol 1,4,5-trisphosphate (IP_3) receptor (*IP3R*),
418 ryanodine receptor 2 (*RyR2*), ryanodine receptor 3 (*RyR3*) and sarcoplasmic reticulum
419 Ca^{2+} -ATPase (*SERCA*) (Figure 3C).

420 Having demonstrated that inhibitors of Rho kinase and ER stress ameliorate
421 hypercontractile responses in CADASIL vessels, some of the elements of these
422 systems were assessed. Vascular expression of the Rho guanine nucleotide-
423 exchange factors (GEFs), *Pdz* and *Larg*, was increased in TgNotch3^{R169C} mice
424 compared to TgNotch3^{WT} (Figure 4A). Gene expression of *p115* was unchanged in

425 TgNotch3^{R169C} mice. Arteries from TgNotch3^{R169C} mice also exhibited increased
426 transcription of ER stress genes: X-box binding protein 1 (*XBP1*), activating
427 transcription factor 4 (*ATF4*), binding immunoglobulin protein (*BiP*), and C/EBP
428 homologous protein (*CHOP*) (Figure 4B). Increased ER stress during Notch3 gain-of-
429 function mutation was confirmed in mesenteric arteries stained with BiP, a major ER
430 chaperone and a central regulator of ER stress, which was significantly increased in
431 TgNotch3^{R169C} vessels (Figure 4C). ERO1, a natural UPR target promoter triggered
432 by ER stress, was also increased in TgNotch3^{R169C} mesenteric arteries (Figure 4D).
433 Together these data indicate that a Notch3 gain-of-function mutation during CADASIL
434 is associated with upregulation of Rho kinase, ER stress responses and changes in
435 Ca²⁺ homeostasis in small peripheral arteries.

436 **Notch3 gain-of-function impairs NO signalling in peripheral small arteries**

437 Impaired vasorelaxation in TgNotch3^{R169C} mesenteric arteries was associated with
438 alterations in signalling pathways that control endothelial and vascular
439 contraction/dilation. As shown in figure 5A, phosphorylation of the inhibitory site of
440 endothelial nitric oxide synthase (eNOS; Thr⁴⁹⁵) was significantly increased in
441 TgNotch3^{R169C} mice whereas phosphorylation of the activator site of eNOS (Ser¹¹⁷⁷)
442 was unchanged (Supplementary figure 3). These responses were associated with
443 decreased cGMP levels in CADASIL VSMCs (Figure 5C). cGMP levels were not
444 altered by fasudil or 4-PBA in CADASIL and control VSMCs.

445 **Impaired vasorelaxation involves redox-sensitive PKG-dependent pathways in**

446 **TgNotch3^{R169C} mice**

447 To further dissect possible mechanisms underlying reduced vasorelaxation and
448 perturbed vascular NO/cGMP signalling in TgNotch3^{R169C} mice, we interrogated
449 vasodilator pathways mediated by redox-sensitive protein kinase G (PKG), which has

450 been shown to regulate vasorelaxation through H₂O₂-dependent pathways.
451 Vasorelaxation concentration-response curves to BAY 58-2667, a potent soluble
452 guanylyl cyclase (sGC) activator, and 8-Br-cGMP, which activates cGMP-dependent
453 PKG, were performed in mesenteric arteries from TgNotch3^{R169C} mice. Vasodilation
454 induced by both BAY 58-2667 (Figure 6A) and 8-Br-cGMP, a cGMP analogue (Figure
455 6B), was reduced in vessels from TgNotch3^{R169C} mice, suggesting an impairment in
456 sGC and PKG activity in these mice. At the molecular level, this was associated with
457 augmented generation of vascular ROS (Figure 6C), systemic oxidative stress
458 (Supplementary figure 4), increased oxidation of sGCβ1 (Figure 6D) and increased
459 expression of Nox1 in TgNotch3^{R169C} arteries (Figure 6E). Associated with increased
460 NADPH-derived O₂⁻ production was reduced bioavailability of H₂O₂, a putative
461 endothelium-derived relaxing factor (EDRF) [32, 33], in TgNotch3^{R169C} arteries (Figure
462 6F). Vascular expression of the antioxidant enzymes catalase and glutathione
463 peroxidase 1 (GPX1), which catalyse H₂O₂ to O₂ and H₂O, was reduced in CADASIL
464 mice (Figures 6G, 6H).

465 **Impaired sGC/cGMP and oxidative status in VSMCs and cerebral vessels from** 466 **patients with CADASIL**

467 To determine whether the vascular alterations identified in experimental models of
468 CADASIL are also present in human vessels, we explored some of the molecular
469 processes in VSMCs from patients with CADASIL. We also studied post-mortem brain
470 sections from patients who had CADASIL. As shown in figure 7A, levels of cGMP, an
471 important regulator of VSMC relaxation, were significantly reduced in VSMCs from
472 patients with CADASIL. Pre-treatment of VSMCs with fasudil or 4-PBA normalised
473 cGMP levels (Figure 7A). Oxidation of sGCβ1 was higher in CADASIL VSMCs
474 compared with control VSMCs (Figure 7B). We previously showed that VSMCs from

475 CADASIL patients have increased oxidative stress [12]. Levels of DNA oxidation,
476 assessed as the 8-OHG content, were significantly increased in brain vessels in
477 CADASIL patients compared with controls (Figures 7C, 7D).

478

479 **Discussion**

480 CADASIL is typically associated with small vessel disease of the brain causing
481 migraine with aura, ischaemic structural changes in white and deep grey matter
482 structures, cognitive impairment, and recurrent small vessel ischemic strokes leading
483 to vascular dementia [7, 9]. However, growing pre-clinical and clinical evidence
484 indicates that peripheral small arteries are also dysfunctional in CADASIL [11, 34-36].
485 We recently reported that patients with CADASIL have impaired endothelial function
486 and altered vascular contractile responses, processes associated with increased Rho
487 kinase activation and ER stress [12]. To advance these findings and to further dissect
488 underlying molecular mechanisms we studied TgNotch3^{R169C} mice that express the
489 CADASIL-causing Notch3(R169C) mutant protein [22]. We also probed some
490 molecular processes in cerebral vessels in brain tissue obtained post-mortem from
491 patients with CADASIL. Major findings from our study show that peripheral small
492 arteries from TgNotch3^{R169C} mice exhibit GOM deposits, typically observed in the
493 cerebrovascular bed in CADASIL. Functional alterations were defined by
494 hypercontractility and impaired endothelium-dependent and -independent
495 vasorelaxation. At the molecular level, vascular abnormalities in TgNotch3^{R169C} mice
496 were linked to dysregulation of Ca²⁺ homeostasis, Rho kinase activation, ER stress
497 response, and blunting of the eNOS/NO/sGC/cGMP pathway. Perturbed VSMC
498 signalling and vascular dysfunction in CADASIL mice were associated with an
499 increase in ROS production, highlighting a role for redox-dependent processes in the

500 vasculopathy of CADASIL. These phenomena in mice were recapitulated in human
501 studies, where we observed increased oxidative stress-induced DNA and RNA
502 damage and sGC oxidation in VSMCs and cerebral arteries from CADASIL patients.
503 Our novel findings indicate that a Notch3 gain-of-function mutation is associated with
504 upregulation of Rho kinase, ER stress responses and redox-sensitive processes
505 affecting the eNOS/sGC/cGMP axis leading to vascular dysfunction.

506 Pathological hallmarks of the vasculopathy in CADASIL include accumulation
507 of the extracellular domain of Notch3 (Notch3^{ECD}) and the presence of GOM deposits
508 on SMCs from small arteries [37, 38]. In aging mice GOM deposits progress in size
509 over time and new GOM deposits are continuously being formed [38]. Here we
510 demonstrated by electron microscopy that peripheral arteries from TgNotch3^{R169C} mice
511 have GOM deposits, processes associated with altered ECM protein expression and
512 enlargement of SMC intercellular space in arteries. These findings recapitulate
513 features in cerebral vessels [37], confirming that manifestations of the Notch3 mutation
514 in CADASIL are not restricted to the cerebrovascular system but are likely present in
515 small arteries in multiple vascular beds [37].

516 We provide evidence that CADASIL-causing Notch3 mutations cause
517 functional changes in peripheral arteries. Vasoconstriction to three different agonists
518 (phenylephrine, Ang II and U44619), was increased in TgNotch3^{R169C} mice, indicating
519 a generalized phenomenon rather than an agonist-specific effect. These findings are
520 in contrast to what was demonstrated in CADASIL patients where peripheral arteries
521 showed reduced vasoreactivity [11, 12, 39]. Reasons for these differences are unclear
522 but may relate to relative chronicity of the disease, since human studies were carried
523 out in patients later in life, whereas our experimental studies here were performed in
524 mice at a relatively young age (6 months). Vascular smooth muscle cell contraction is

525 regulated primarily by dynamic changes in Ca^{2+} homeostasis and Ca^{2+} channel
526 activity/expression [40]. Our findings showed hypercontractility of TgNotch3^{R169C}
527 arteries, in addition to augmented agonist-stimulated Ca^{2+} transients and increased
528 expression of Ca^{2+} channels. These processes are highly regulated since Cav1.1,
529 IP3R and RyR1 were upregulated in CADASIL mice, whereas TRPM2, SERCA, RyR2
530 and RyR3 were not altered compared with control mice. Previous studies showed an
531 important role for Notch in Ca^{2+} regulation, since Notch increases expression/activity
532 of store-operated Ca^{2+} entry (SOCE) and canonical transient receptor potential
533 (TRPC6) channels in VSMCs [41]. Moreover Ca^{2+} channel blockers seem to improve
534 cognitive decline and cerebral hypoperfusion in CADASIL patients [42], although this
535 aspect warrants further investigation.

536 Vascular smooth muscle cells are highly plastic and in disease states undergo
537 phenotypic switching from a contractile to a proliferative and pro-inflammatory state.
538 While VSMC contraction is triggered by an increase in $[\text{Ca}^{2+}]_i$ which promotes actin-
539 myosin interaction, it is also regulated by Ca^{2+} -independent processes involving RhoA-
540 Rho kinase and MAP kinases, ROS amongst other systems [40]. These phenomena
541 are especially important in pathological conditions as we demonstrate here, where
542 vascular dysfunction was associated not only with amplification of Ca^{2+} transients, but
543 also with systems involving Rho kinase, oxidative and ER stress. Pharmacological
544 inhibitors of Rho kinase and ER stress normalised hypercontractile responses in
545 CADASIL mice, indicating involvement of these systems in Notch3-regulated
546 contraction. Supporting this notion, at the molecular level, elements of RhoA/Rho
547 kinase signalling, and the ER stress response were perturbed in TgNotch3^{R169C}
548 VSMCs. RhoA, a member of the Rho GTPase family and regulated by Rho GEFs, is
549 a master regulator of cytoskeletal dynamics and VSMC function [43, 44]. Expression

550 of Rho GEFs was altered in CADASIL mice. In particular, mRNA expression of PDZ
551 and LARG, but not p115, was increased in TgNotch3^{R169C} vessels. This is not
552 surprising since PDZ and LARG are crucial elements involved in VSMC contractile
553 signalling, whereas p115 influences destabilization of endothelial cell-cell junctions
554 [44]. Our findings are in line with those observed in VSMCs from CADASIL patients,
555 where the RhoA/Rho kinase pathway is upregulated [12].

556 Among the many systems implicated in abnormal VSMC function in CADASIL,
557 is abnormal handling and folding of mutant Notch3 protein, processes that involve the
558 ER [45]. Under stress conditions, proteins become misfolded and accumulate in the
559 ER provoking the unfolded ER protein response. Prolonged retention of ER mutant
560 Notch3 aggregates and ER stress influence VSMC function and GOM deposition and
561 may be important pathogenic mechanisms contributing to the vasculopathy in
562 CADASIL. Supporting this, expression of ER stress markers XBP1, ATF4, Bip, CHOP
563 and ERO1 was increased in CADASIL vessels, processes that involve Rho kinase
564 activation as we previously demonstrated [12]. ER stress is downstream of Rho kinase
565 because fasudil inhibits ER stress-induced responses by modulating the unfolded
566 protein response in vascular cells [46]. Functionally, ER stress influences vascular
567 function since 4-PBA attenuated hypercontractile responses in TgNotch3^{R169C} mice.
568 Corroborating these findings, previous studies showed that aberrant ER stress in
569 VSMCs causes increased vascular contraction [47].

570 Similar to what we found in peripheral and cerebral vessels in CADASIL
571 patients [12, 48], agonist-stimulated relaxation was impaired in mesenteric arteries in
572 TgNotch3^{R169C} mice. Both endothelium-dependent and endothelium-independent
573 vasorelaxation were reduced in CADASIL mice, analogous to what was reported in
574 the cerebrovascular system of these mice [49]. Endothelial NOS is the primary source

575 of NO in endothelial cells and is the key regulator of endothelial function [50]. Impaired
576 endothelium-dependent relaxation in TgNotch3^{R169C} arteries was associated with
577 decreased eNOS phosphorylation and oxidative stress, which lead to reduced eNOS
578 activation and decreased bioavailability of the vasodilator NO, which is vaso-injurious
579 [50]. Notch signalling plays an important role in cell-cell communication between
580 endothelial cells and VSMCs, but exactly how VSMC Notch3 influences endothelial
581 cell function remains unclear. It may be possible that endothelial injury is secondary
582 to VSMC dysfunction, vascular remodelling and GOM accumulation.

583 The importance of perturbed VSMC function in CADASIL is further evidenced
584 by our findings that endothelium-independent vasorelaxation (SNP-induced
585 responses) was impaired in TgNotch3^{R169C} mice. VSMCs constitute the bulk of the
586 vascular media and are largely responsible for maintaining vascular
587 contraction/dilation and arterial tone. The major molecular system controlling VSMC
588 dilation is the sGC/cGMP pathway. Activation of sGC increases production of the
589 second messenger cGMP, which influences downstream signalling through cGMP-
590 dependent protein kinase (PKG) [51, 52]. PKG is a potent vasodilator and mediates
591 effects in part through H₂O₂ [33]. PKG is also regulated by oxidant-induced interprotein
592 disulphide formation. This oxidation-induced activation of PKG represents an alternate
593 cGMP-independent mechanism regulating vascular function [53, 54]. The potential
594 role of sGC/cGMP/PKG in endothelium-independent vasorelaxation in CADASIL was
595 probed in VSMCs and vessels from TgNotch3^{R169C} mice and patients with CADASIL.
596 Vascular sensitivity to BAY 58-2667, a sGC activator that bypasses the impaired
597 NO/sGC/cGMP pathway by activating the oxidized form of the enzyme [55], was
598 reduced in TgNotch3^{R169C} mice, suggesting less activity of sGC due to its higher
599 oxidation. Supporting this, vascular oxidative stress and associated oxidation of

600 sGC β 1 were increased in tissue from TgNotch3^{R169C} mice. Decreased activation of
601 sGC culminates in reduced PKG activity and decreased vasodilation, which might be
602 aggravated by decreased H₂O₂ levels, since H₂O₂ is an important vasodilator [53, 54,
603 56]. This may be important in TgNotch3^{R169C} mice, where downregulation of the
604 sGC/cGMP system was associated with decreased vascular H₂O₂ production
605 compared with control mice. While these observations were made in peripheral
606 vessels, they are especially pertinent in the cerebral circulation where H₂O₂ rather than
607 NO seems to be the major vasodilator [33, 57]. Hence, cerebrovascular dysfunction in
608 CADASIL may be linked, at least in part, to defective H₂O₂-mediated vasorelaxation.
609 Vascular H₂O₂ downregulation seems to be associated with increased catalase and
610 GPX1 whereas increased superoxide levels may be linked to Nox1, an important
611 source of vascular ROS [30]. Translating our pre-clinical studies to humans, we
612 studied VSMCs and brain sections from CADASIL patients and found increased
613 vascular oxidative stress and sGC β 1 oxidation and extensive DNA damage. These
614 vascular abnormalities may play a role in cerebrovascular pathology underlying
615 CADASIL.

616 In conclusion, we demonstrate that peripheral small arteries from
617 TgNotch3^{R169C} mice exhibit hypercontractility, impaired endothelium-dependent and -
618 independent vasorelaxation, processes associated with altered Ca²⁺ homeostasis,
619 upregulation of Rho kinase, activation of ER stress and impaired eNOS/sGC/cGMP
620 signalling. We identify novel pathways whereby Notch3 gain-of-function mutation
621 causes vascular dysfunction and highlight the concept that, although the arteriopathy
622 of CADASIL is primarily cerebral, peripheral vessels are also affected. This has
623 important clinical implications, because systemic vasculopathy and dysfunctional
624 vasoreactivity may be associated with peripheral vascular disease in CADASIL

625 patients [34]. Additionally, given the current elusive knowledge of the downstream
626 Notch3-mediated mechanisms in the vasculature and the ubiquitous expression in all
627 VSMCs, our data are not just useful for examining CADASIL, but are translatable to
628 vascular Notch3 signalling in general and in other vascular diseases.

629 **Data availability Statement**

630 The data underlying this study will be shared on request to the corresponding author.

631

632 **Clinical Perspectives**

633 • **Background as to why the study was undertaken**

634 CADASIL is typically defined as a small vessel disease of the brain. However growing
635 evidence indicates that peripheral small vessels are also dysfunctional, which may be
636 a marker of cerebral vessel dysfunction and/or contribute to peripheral vascular
637 disease. Molecular mechanisms underlying the peripheral vasculopathy in CADASIL
638 remain unclear, although Rho kinase and ER- and oxidative stress may be important
639 as we showed. Here we advance this notion and define novel signaling pathways in
640 the vasculopathy of CADASIL

641 **A brief summary of the results**

642 CADASIL mice with Notch3 gain of function mutation exhibit peripheral vascular
643 dysfunction characterised by impaired vasorelaxation and hypercontractility. These
644 process involve altered vascular Ca^{2+} homeostasis, upregulation of Rho kinase, and
645 ER-and oxidative stress that cause hyperoxidation of vascular signaling molecules and
646 blunting of the eNOS/sGC/cGMP pathway. Findings in CADASIL mice were
647 recapitulated in post-mortem cerebral vessels from patients with CADASIL

648 **The potential significance of the results to human health and disease**

649 We identify novel pathways whereby Notch3 gain-of-function mutation causes
650 vascular dysfunction and highlight the concept that, although the arteriopathy of
651 CADASIL is primarily cerebral, peripheral vessels are also affected. This has important
652 clinical implications, because systemic vasculopathy may predispose to peripheral
653 vascular disease in CADASIL patients. Additionally, given the gap in knowledge of
654 Notch3-mediated downstream pathways and the ubiquitous expression in VSMCs, our
655 data provide insights into vascular Notch3 signalling in general, beyond CADASIL.

656

657 **Competing Interests**

658 None.

659

660 **Funding**

661 This study was supported by grants from the British Heart Foundation (BHF)
662 (RE/13/5/30177; 18/6/34217) and the MRC (MC-PC-15076). The CADASIL biopsy
663 samples were funded by grants from The Neurosciences Foundation and The Stroke
664 Association (TSA 2013/02) and the control biopsy samples were funded by grants from
665 the Department of Medicine, University of Ottawa and the Canadian Institutes of
666 Health Research, Canada. RMT is supported through a BHF Chair award
667 (CH/12/29762) and ACM is supported through a Walton Foundation fellowship,
668 University of Glasgow.

669

670 **Acknowledgments**

671 Our sincere thanks to Prof. Anne Joutel, who kindly provided the CADASIL mouse
672 model. Thanks to Dr Willie Stewart for expert help with the neuropathology (Institute
673 of Neuroscience & Psychology, University of Glasgow & Queen Elizabeth University
674 Hospital). We thank Margaret Mullen for all support with the electron microscopy

675 experiments; Dr Adam Harvey and Wendy Beattie for the help with the human cells
676 and mouse colonies; Laura Haddow and John McAbeny from the BHF Myography &
677 Imaging Core Facility; Jackie Thomson and Ross Hepburn for all the lab support. We
678 are also very grateful to the patients and volunteers who participated in this study. We
679 acknowledge the support of NHS Research Scotland (NRS), NHS Greater Glasgow
680 and Clyde Biorepository.

681

682 **Abbreviations**

683 CADASIL – Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and
684 Leukoencephalopathy

685 Notch3^{ECD} - extracellular domain of Notch3

686 GOM - granular osmiophilic material

687 VSMC - vascular smooth muscle cells

688 ER - endoplasmic reticulum

689 sGC – soluble guanylate cyclase

690 NO – nitric oxide

691 eNOS – endothelial nitric oxide synthase

692 cGMP – cyclic guanosine monophosphate

693 Kv1 - voltage-dependent potassium (Kv1) channels

694 ROS - reactive oxygen species

695 FBS - fetal bovine serum

696 4-PBA - 4-phenylbutyrate

697 SOH - sulfenic acid groups

698 8-OHG - 8-Hydroxyguanosine

699 UPR - unfolded protein responses

- 700 H₂O₂ - Hydrogen peroxide
- 701 TBARS - Thiobarbituric acid reactive substances
- 702 ACh – acetylcholine
- 703 SNP – sodium nitroprusside
- 704 Phe - phenylephrine
- 705 Cav1.1 - Ca²⁺ channels voltage-dependent L-type calcium channel, subunit α_{1S}
- 706 TRPM2 - transient receptor potential cation channel, subfamily M, member 2
- 707 RyR - ryanodine receptor
- 708 IP₃R - inositol 1,4,5-trisphosphate
- 709 SERCA - sarcoplasmic reticulum Ca²⁺-ATPase
- 710 GEFs - guanine nucleotide-exchange factors
- 711 XBP1 - X-box binding protein 1
- 712 ATF4 - activating transcription factor 4
- 713 BiP - binding immunoglobulin protein
- 714 CHOP - C/EBP homologous protein
- 715 GPX1 - glutathione peroxidase 1
- 716 SOCE - store-operated Ca²⁺ entry (SOCE)
- 717 TRPC6 - canonical transient receptor potential

718

719 **References**

- 720 1. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: Cell fate control
721 and signal integration in development. *Science*. 1999;**284**:770-776
- 722 2. Fleming RJ. Structural conservation of notch receptors and ligands. *Semin Cell*
723 *Dev Biol*. 1998;**9**:599-607
- 724 3. Kopan R, Ilagan MX. The canonical notch signaling pathway: Unfolding the
725 activation mechanism. *Cell*. 2009;**137**:216-233
- 726 4. Morris HE, Neves KB, Montezano AC, MacLean MR, Touyz RM. Notch3
727 signalling and vascular remodelling in pulmonary arterial hypertension. *Clin Sci*
728 (*Lond*). 2019;**133**:2481-2498

- 729 5. Baeten JT, Lilly B. Notch signaling in vascular smooth muscle cells. *Adv*
730 *Pharmacol.* 2017;**78**:351-382
- 731 6. Wang T, Baron M, Trump D. An overview of notch3 function in vascular smooth
732 muscle cells. *Prog Biophys Mol Biol.* 2008;**96**:499-509
- 733 7. Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P, Alamowitch
734 S, Domenga V, Cecillion M, Marechal E, Maciazek J, Vayssiere C, Cruaud C,
735 Cabanis EA, Ruchoux MM, Weissenbach J, Bach JF, Bousser MG, Tournier-
736 Lasserre E. Notch3 mutations in cadasil, a hereditary adult-onset condition
737 causing stroke and dementia. *Nature.* 1996;**383**:707-710
- 738 8. Ishiko A, Shimizu A, Nagata E, Takahashi K, Tabira T, Suzuki N. Notch3
739 ectodomain is a major component of granular osmiophilic material (gom) in
740 cadasil. *Acta Neuropathol.* 2006;**112**:333-339
- 741 9. Moreton FC, Razvi SS, Davidson R, Muir KW. Changing clinical patterns and
742 increasing prevalence in cadasil. *Acta neurologica Scandinavica.*
743 2014;**130**:197-203
- 744 10. Di Donato I, Bianchi S, De Stefano N, Dichgans M, Dotti MT, Duering M,
745 Jouvent E, Korczyn AD, Lesnik-Oberstein SA, Malandrini A, Markus HS,
746 Pantoni L, Penco S, Rufa A, Sinanovic O, Stojanov D, Federico A. Cerebral
747 autosomal dominant arteriopathy with subcortical infarcts and
748 leukoencephalopathy (cadasil) as a model of small vessel disease: Update on
749 clinical, diagnostic, and management aspects. *BMC medicine.* 2017;**15**:41
- 750 11. Moreton FC, Cullen B, Delles C, Santosh C, Gonzalez RL, Dani K, Muir KW.
751 Vasoreactivity in cadasil: Comparison to structural mri and neuropsychology.
752 *Journal of cerebral blood flow and metabolism : official journal of the*
753 *International Society of Cerebral Blood Flow and Metabolism.* 2018;**38**:1085-
754 1095
- 755 12. Neves KB, Harvey AP, Moreton F, Montezano AC, Rios FJ, Alves-Lopes R,
756 Nguyen Dinh Cat A, Rocchiccioli P, Delles C, Joutel A, Muir K, Touyz RM. Er
757 stress and rho kinase activation underlie the vasculopathy of cadasil. *JCI*
758 *Insight.* 2019;**4**
- 759 13. Ling C, Liu Z, Song M, Zhang W, Wang S, Liu X, Ma S, Sun S, Fu L, Chu Q,
760 Belmonte JCI, Wang Z, Qu J, Yuan Y, Liu GH. Modeling cadasil vascular
761 pathologies with patient-derived induced pluripotent stem cells. *Protein Cell.*
762 2019;**10**:249-271
- 763 14. Capone C, Dabertrand F, Baron-Menguy C, Chalaris A, Ghezali L, Domenga-
764 Denier V, Schmidt S, Huneau C, Rose-John S, Nelson MT, Joutel A.
765 Mechanistic insights into a timp3-sensitive pathway constitutively engaged in
766 the regulation of cerebral hemodynamics. *Elife.* 2016;**5**
- 767 15. Ihalainen S, Soliymani R, Iivanainen E, Mykkanen K, Sainio A, Poyhonen M,
768 Elenius K, Jarvelainen H, Viitanen M, Kalimo H, Baumann M. Proteome
769 analysis of cultivated vascular smooth muscle cells from a cadasil patient. *Mol*
770 *Med.* 2007;**13**:305-314
- 771 16. Monet-Lepretre M, Haddad I, Baron-Menguy C, Fouillot-Panchal M, Riani M,
772 Domenga-Denier V, Dussaule C, Cognat E, Vinh J, Joutel A. Abnormal
773 recruitment of extracellular matrix proteins by excess notch3 ecd: A new
774 pathomechanism in cadasil. *Brain.* 2013;**136**:1830-1845
- 775 17. Dong H, Blaivas M, Wang MM. Bidirectional encroachment of collagen into the
776 tunica media in cerebral autosomal dominant arteriopathy with subcortical
777 infarcts and leukoencephalopathy. *Brain Res.* 2012;**1456**:64-71

- 778 18. Panahi M, Yousefi Mesri N, Samuelsson EB, Coupland KG, Forsell C, Graff C,
779 Tikka S, Winblad B, Viitanen M, Karlstrom H, Sundstrom E, Behbahani H.
780 Differences in proliferation rate between cadasil and control vascular smooth
781 muscle cells are related to increased tgfbeta expression. *J Cell Mol Med.*
782 2018;**22**:3016-3024
- 783 19. Tikka S, Ng YP, Di Maio G, Mykkanen K, Siitonen M, Lepikhova T, Poyhonen
784 M, Viitanen M, Virtanen I, Kalimo H, Baumann M. Cadasil mutations and shrna
785 silencing of notch3 affect actin organization in cultured vascular smooth muscle
786 cells. *J Cereb Blood Flow Metab.* 2012;**32**:2171-2180
- 787 20. Viitanen M, Sundstrom E, Baumann M, Poyhonen M, Tikka S, Behbahani H.
788 Experimental studies of mitochondrial function in cadasil vascular smooth
789 muscle cells. *Exp Cell Res.* 2013;**319**:134-143
- 790 21. Dabertrand F, Kroigaard C, Bonev AD, Cognat E, Dalsgaard T, Domenga-
791 Denier V, Hill-Eubanks DC, Brayden JE, Joutel A, Nelson MT. Potassium
792 channelopathy-like defect underlies early-stage cerebrovascular dysfunction in
793 a genetic model of small vessel disease. *Proc Natl Acad Sci U S A.*
794 2015;**112**:E796-805
- 795 22. Baron-Menguy C, Domenga-Denier V, Ghezali L, Faraci FM, Joutel A.
796 Increased notch3 activity mediates pathological changes in structure of
797 cerebral arteries. *Hypertension.* 2017;**69**:60-70
- 798 23. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure
799 and endothelial dysfunction in human essential hypertension by the angiotensin
800 receptor antagonist losartan. *Circulation.* 2000;**101**:1653-1659
- 801 24. Montezano AC, Lopes RA, Neves KB, Rios F, Touyz RM. Isolation and culture
802 of vascular smooth muscle cells from small and large vessels. *Methods Mol*
803 *Biol.* 2017;**1527**:349-354
- 804 25. Graham DI, Gentleman SM, Lynch A, Roberts GW. Distribution of beta-amyloid
805 protein in the brain following severe head injury. *Neuropathol Appl Neurobiol.*
806 1995;**21**:27-34
- 807 26. Lacombe P, Oligo C, Domenga V, Tournier-Lasserre E, Joutel A. Impaired
808 cerebral vasoreactivity in a transgenic mouse model of cerebral autosomal
809 dominant arteriopathy with subcortical infarcts and leukoencephalopathy
810 arteriopathy. *Stroke.* 2005;**36**:1053-1058
- 811 27. Nelson KJ, Klomsiri C, Codreanu SG, Soito L, Liebler DC, Rogers LC, Daniel
812 LW, Poole LB. Use of dimedone-based chemical probes for sulfenic acid
813 detection methods to visualize and identify labeled proteins. *Methods Enzymol.*
814 2010;**473**:95-115
- 815 28. Kasai H, Crain PF, Kuchino Y, Nishimura S, Ootsuyama A, Tanooka H.
816 Formation of 8-hydroxyguanine moiety in cellular DNA by agents producing
817 oxygen radicals and evidence for its repair. *Carcinogenesis.* 1986;**7**:1849-1851
- 818 29. Wang M, Wey S, Zhang Y, Ye R, Lee AS. Role of the unfolded protein response
819 regulator grp78/bip in development, cancer, and neurological disorders.
820 *Antioxid Redox Signal.* 2009;**11**:2307-2316
- 821 30. Lopes RA, Neves KB, Tostes RC, Montezano AC, Touyz RM. Downregulation
822 of nuclear factor erythroid 2-related factor and associated antioxidant genes
823 contributes to redox-sensitive vascular dysfunction in hypertension.
824 *Hypertension.* 2015;**66**:1240-1250
- 825 31. Lorenzi T, Ragno M, Paolinelli F, Castellucci C, Scarpelli M, Morroni M. Cadasil:
826 Ultrastructural insights into the morphology of granular osmiophilic material.
827 *Brain Behav.* 2017;**7**:e00624

- 828 32. Matoba T, Shimokawa H, Nakashima M, Hirakawa Y, Mukai Y, Hirano K,
829 Kanaide H, Takeshita A. Hydrogen peroxide is an endothelium-derived
830 hyperpolarizing factor in mice. *J Clin Invest*. 2000;**106**:1521-1530
- 831 33. Shimokawa H. Hydrogen peroxide as an endothelium-derived hyperpolarizing
832 factor. *Pflugers Arch*. 2010;**459**:915-922
- 833 34. Briceno DF, Bhattacharjee MB, Supsupin E, Jr., Navarro P, Bhattacharjee M.
834 Peripheral artery disease as a manifestation of cerebral autosomal dominant
835 arteriopathy with subcortical infarcts and leukoencephalopathy (cadasil) and
836 practical implications. *Circulation*. 2013;**127**:e568-570
- 837 35. Fujiwara Y, Mizuno T, Okuyama C, Nagakane Y, Watanabe-Hosomi A, Kondo
838 M, Kuriyama N, Tokuda T, Matsushima S, Nishimura T, Nakagawa M.
839 Simultaneous impairment of intracranial and peripheral artery vasoreactivity in
840 cadasil patients. *Cerebrovasc Dis*. 2012;**33**:128-134
- 841 36. Stenborg A, Kalimo H, Viitanen M, Terent A, Lind L. Impaired endothelial
842 function of forearm resistance arteries in cadasil patients. *Stroke*.
843 2007;**38**:2692-2697
- 844 37. Ruchoux MM, Domenga V, Brulin P, Maciazek J, Limol S, Tournier-Lasserre
845 E, Joutel A. Transgenic mice expressing mutant notch3 develop vascular
846 alterations characteristic of cerebral autosomal dominant arteriopathy with
847 subcortical infarcts and leukoencephalopathy. *Am J Pathol*. 2003;**162**:329-342
- 848 38. Gravesteijn G, Munting LP, Overzier M, Mulder AA, Hegeman I, Derieppe M,
849 Koster AJ, van Duinen SG, Meijer OC, Aartsma-Rus A, van der Weerd L, Jost
850 CR, van den Maagdenberg A, Rutten JW, Lesnik Oberstein SAJ. Progression
851 and classification of granular osmiophilic material (gom) deposits in functionally
852 characterized human notch3 transgenic mice. *Transl Stroke Res*. 2019
- 853 39. Hussain MB, Singhal S, Markus HS, Singer DR. Abnormal vasoconstrictor
854 responses to angiotensin ii and noradrenaline in isolated small arteries from
855 patients with cerebral autosomal dominant arteriopathy with subcortical infarcts
856 and leukoencephalopathy (cadasil). *Stroke*. 2004;**35**:853-858
- 857 40. Touyz RM, Alves-Lopes R, Rios FJ, Camargo LL, Anagnostopoulou A, Arner
858 A, Montezano AC. Vascular smooth muscle contraction in hypertension.
859 *Cardiovasc Res*. 2018;**114**:529-539
- 860 41. Smith KA, Voiriot G, Tang H, Fraidenburg DR, Song S, Yamamura H,
861 Yamamura A, Guo Q, Wan J, Pohl NM, Tauseef M, Bodmer R, Ocorr K,
862 Thistlethwaite PA, Haddad GG, Powell FL, Makino A, Mehta D, Yuan JX. Notch
863 activation of ca(2+) signaling in the development of hypoxic pulmonary
864 vasoconstriction and pulmonary hypertension. *Am J Respir Cell Mol Biol*.
865 2015;**53**:355-367
- 866 42. Mizuno T, Kondo M, Ishigami N, Tamura A, Itsukage M, Koizumi H, Isayama
867 R, Hosomi A, Nagakane Y, Tokuda T, Sugimoto E, Ushijima Y, Nakagawa M.
868 Cognitive impairment and cerebral hypoperfusion in a cadasil patient improved
869 during administration of lomerizine. *Clin Neuropharmacol*. 2009;**32**:113-116
- 870 43. van Buul JD, Geerts D, Huveneers S. Rho gaps and gefs: Controlling switches
871 in endothelial cell adhesion. *Cell Adh Migr*. 2014;**8**:108-124
- 872 44. Hodge RG, Ridley AJ. Regulating rho gtpases and their regulators. *Nat Rev*
873 *Mol Cell Biol*. 2016;**17**:496-510
- 874 45. Takahashi K, Adachi K, Yoshizaki K, Kunitomo S, Kalaria RN, Watanabe A.
875 Mutations in notch3 cause the formation and retention of aggregates in the
876 endoplasmic reticulum, leading to impaired cell proliferation. *Hum Mol Genet*.
877 2010;**19**:79-89

- 878 46. Kawanami D, Matoba K, Okada R, Tsukamoto M, Kinoshita J, Ishizawa S,
879 Kanazawa Y, Yokota T, Utsunomiya K. Fasudil inhibits er stress-induced vcam-
880 1 expression by modulating unfolded protein response in endothelial cells.
881 *Biochem Biophys Res Commun*. 2013;**435**:171-175
- 882 47. Liang B, Wang S, Wang Q, Zhang W, Viollet B, Zhu Y, Zou MH. Aberrant
883 endoplasmic reticulum stress in vascular smooth muscle increases vascular
884 contractility and blood pressure in mice deficient of amp-activated protein
885 kinase-alpha2 in vivo. *Arterioscler Thromb Vasc Biol*. 2013;**33**:595-604
- 886 48. Chabriat H, Pappata S, Ostergaard L, Clark CA, Pachot-Clouard M, Vahedi K,
887 Jobert A, Le Bihan D, Bousser MG. Cerebral hemodynamics in cadasil before
888 and after acetazolamide challenge assessed with mri bolus tracking. *Stroke*.
889 2000;**31**:1904-1912
- 890 49. Capone C, Cognat E, Ghezali L, Baron-Menguy C, Aubin D, Mesnard L, Stohr
891 H, Domenga-Denier V, Nelson MT, Joutel A. Reducing timp3 or vitronectin
892 ameliorates disease manifestations in cadasil mice. *Ann Neurol*. 2016;**79**:387-
893 403
- 894 50. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease:
895 From marvel to menace. *Circulation*. 2006;**113**:1708-1714
- 896 51. Park M, Sandner P, Krieg T. Cgmp at the centre of attention: Emerging
897 strategies for activating the cardioprotective pkg pathway. *Basic Res Cardiol*.
898 2018;**113**:24
- 899 52. Cuello F, Eaton P. Cysteine-based redox sensing and its role in signaling by
900 cyclic nucleotide-dependent kinases in the cardiovascular system. *Annu Rev*
901 *Physiol*. 2019;**81**:63-87
- 902 53. Dou D, Zheng X, Liu J, Xu X, Ye L, Gao Y. Hydrogen peroxide enhances
903 vasodilatation by increasing dimerization of cgmp-dependent protein kinase
904 type ialpha. *Circ J*. 2012;**76**:1792-1798
- 905 54. Sheehe JL, Bonev AD, Schmoker AM, Ballif BA, Nelson MT, Moon TM,
906 Dostmann WR. Oxidation of cysteine 117 stimulates constitutive activation of
907 the type ialpha cgmp-dependent protein kinase. *J Biol Chem*. 2018;**293**:16791-
908 16802
- 909 55. Shah RC, Sanker S, Wood KC, Durgin BG, Straub AC. Redox regulation of
910 soluble guanylyl cyclase. *Nitric Oxide*. 2018;**76**:97-104
- 911 56. Stubbert D, Prysyzhna O, Rudyk O, Scotcher J, Burgoyne JR, Eaton P.
912 Protein kinase g ialpha oxidation paradoxically underlies blood pressure
913 lowering by the reductant hydrogen sulfide. *Hypertension*. 2014;**64**:1344-1351
- 914 57. Wei EP, Kontos HA, Beckman JS. Mechanisms of cerebral vasodilation by
915 superoxide, hydrogen peroxide, and peroxynitrite. *Am J Physiol*.
916 1996;**271**:H1262-1266

918

919

920 **Figures and Figure Legends**

921 **Figure 1. GOM deposition in CADASIL peripheral small arteries.** GOM deposits
922 were identified in mesenteric arteries from 24-week-old TgNotch3^{WT} and
923 TgNotch3^{R169C} mice via electron microscopy. Ultrathin vessel sections from
924 TgNotch3^{WT} (A) and TgNotch3^{R169C} (B) mice were examined by electron microscopy
925 (n=2). Vessels from TgNotch3^{R169C} exhibited electron-dense granular deposits
926 corresponding to GOM (arrows) within the basement membrane. SMC, smooth
927 muscle cell; EC, endothelial cell; BM, basal membrane. Magnification 600x; Scale bar
928 5 μ m.

929

930 **Figure 2. Role of Rho kinase signalling pathway and ER stress in the vascular**
931 **dysfunction observed in TgNotch3^{R169C} peripheral small arteries.** Vascular
932 functional responses in mesenteric arteries obtained from 24-week-old TgNotch3^{WT}
933 and TgNotch3^{R169C} in response to phenylephrine (Phe), U46619, Angiotensin II (Ang
934 II), acetylcholine (ACh) and sodium nitroprusside (SNP) was assessed by wire
935 myography. The increase in contraction observed in TgNotch3^{R169C} mice was
936 ameliorated in vessels pre-treated with the Rho kinase inhibitor fasudil (A, C, E) and
937 the ER stress inhibitor 4-PBA (B, D, F) (n=5-6; Two-way ANOVA with Bonferroni post-
938 test). Curves represent the mean \pm SEM. (G) Endothelium-dependent vasorelaxation
939 in response to acetylcholine (ACh) was decreased in TgNotch3^{R169C} vessels, which
940 was improved by the ER stress inhibitor 4-PBA (n=4-5). (H) Endothelium-independent
941 vasorelaxation in response to sodium nitroprusside (SNP) was decreased in
942 TgNotch3^{R169C} vessels (n=9-12). Responses were expressed as percentage of
943 U46619-induced pre-constriction. Curves represent the mean \pm SEM. Two-way
944 ANOVA with Bonferroni post-test. # p<0.05 vs. TgN3^{WT}, † vs. TgN3^{R169C}.

945

946 **Figure 3. Increased $[Ca^{2+}]_i$ transients and Ca^{2+} channels gene expression in**
 947 **TgNotch3^{R169C} VSMCs.** (A) Calcium transients were measured by live cell
 948 fluorescence imaging using the fluoroprobe Cal-520 AM. Representative tracings of
 949 VSMCs $[Ca^{2+}]_i$ responses to U46619 (1 μ mol/L) in TgNotch3^{WT} and TgNotch3^{R169C}
 950 VSMCs in presence or absence of 4-PBA. Experiments were repeated 6 times/group
 951 with >30 cells studied/field. (B) $[Ca^{2+}]_i$ calculated as the area under the curve (n=6;
 952 One-way ANOVA with Dunnett post-test). (C) *Cav1.1*, *TRPM2*, *IP3R*, *SERCA*, *RyR1*,
 953 *RyR2* and *RyR3* gene expression in VSMCs isolated from TgNotch3^{WT} and
 954 TgNotch3^{R169C} mice. Analysis was by qPCR and gene expression was normalised to
 955 GAPDH (n=5-11; One-way ANOVA with Dunnett post-test). Results are expressed as
 956 mean \pm SEM. # p<0.05 vs. TgN3^{WT}, † vs. TgN3^{R169C}.

957

958 **Figure 4. Rho kinase and ER stress markers are increased in TgNotch3^{R169C}**
 959 **arteries.** (A) *PDZ*, *LARG* and *p115* gene expression in mesenteric arteries from FVB,
 960 TgNotch3^{WT} and TgNotch3^{R169C} mice (n=6-8). (B) *XBP1*, *ATF4*, *BiP* and *CHOP* gene
 961 expression in FVB, TgNotch3^{WT} and TgNotch3^{R169C} mice (n=5-8). Analysis was
 962 performed by qPCR and gene expression was normalised to GAPDH (One-way
 963 ANOVA with Dunnett post-test). (C) Representative images and fluorescence
 964 quantification of BiP (ER stress marker) in mesenteric arteries from 24-week-old
 965 TgNotch3^{WT} and TgNotch3^{R169C} mice. Nuclei are in blue (DAPI) and BiP in green.
 966 Scale bars = 20 μ m; 63x (n=4; Student's *t* test). (D) Upper panel: representative
 967 immunoblot for ERO1 in mesenteric arteries from TgNotch3^{WT} and TgNotch3^{R169C}
 968 mice; Lower panels: quantification of ERO1. Protein expression was normalised to β -
 969 actin. Results are expressed as mean \pm SEM *p<0.05 vs FVB, # vs. TgN3^{WT}.

970

971 **Figure 5. Vasodilation impairment in TgNotch3^{R169C} arteries involves**

972 **downregulation of eNOS activity and cGMP levels.** (A) Upper panel: representative

973 immunoblot for the phosphorylation of the inhibitory site of eNOS (Thr⁴⁹⁵) in mesenteric

974 arteries from 24-week-old TgNotch3^{WT} and TgNotch3^{R169C} mice; Lower panels:

975 quantification of p-eNOS. Protein expression was normalised to t-eNOS (n=7;

976 Student's *t* test). (B) Levels of cGMP in VSMCs isolated from TgNotch3^{WT} and

977 TgNotch3^{R169C} mice in presence or absence of fasudil and 4-PBA (n=5-9; One-way

978 ANOVA with Dunnett post-test). Results are expressed as mean±SEM. # *p*<0.05 vs.

979 TgN3^{WT}.

980

981 **Figure 6. Downregulation of NO/sGC/cGMP signalling pathway in VSMCs during**

982 **Notch3 gain-of-function mutation is associated with redox-sensitive processes.**

983 Concentration-response curves to (A) BAY 58-2667 (sGC activator) and (B) 8-Br-

984 cGMP (PKG activator) in TgNotch3^{WT} and TgNotch3^{R169C} mesenteric arteries.

985 Responses were expressed as percentage of U46619-induced pre-constriction (n=4-

986 7; Two-way ANOVA with Bonferroni post-test). (C) Reactive oxygen species (ROS)

987 production measured by lucigenin in mesenteric arteries from 24-week-old

988 TgNotch3^{WT} and TgNotch3^{R169C} mice (n=6-8; Student's *t* test). Results are normalized

989 by protein content. (D) sGCβ1oxidation was also assessed in arteries from

990 TgNotch3^{WT} and TgNotch3^{R169C} mice (pool of five different samples). (E) *Nox1* gene

991 expression in mesenteric arteries from TgNotch3^{WT} and TgNotch3^{R169C} mice. Analysis

992 was by qPCR and gene expression was normalised to GAPDH (n=6-7; Student's *t*

993 test). (F) H₂O₂ levels in TgNotch3^{WT} and TgNotch3^{R169C} mesenteric arteries were

994 measured by Amplex Red (n=6-7; Student's *t* test). (G) *Catalase* and (H) *GPX1* gene

995 expression in mesenteric arteries from TgNotch3^{WT} and TgNotch3^{R169C} mice. Analysis
996 was by qPCR and gene expression was normalised to GAPDH (n=6-8; Student's *t*
997 test). Results are expressed as mean±SEM. # *p*<0.05 vs. TgN3^{WT}.

998

999 **Figure 7. Human CADASIL vessels exhibit increased oxidative stress and sGCβ1**

1000 **oxidation.** (A) Levels of cGMP in VSMCs from control and CADASIL patients in the
1001 presence and absence of fasudil or 4-PBA (n=5; One-way ANOVA with Dunnett post-
1002 test). Results are expressed as mean±SEM. # *p*<0.05 vs. TgN3^{WT}. (B) sGCβ1
1003 oxidation assessed in control and CADASIL VSMCs (pool of five different samples).
1004 (C) Representative images from two different control and CADASIL patients and (D)
1005 analysis of 8-hydroxyguanosine (8-OHG) in brain vessels. Nuclei are in blue (DAPI)
1006 and 8-OHG in green (arrows). Scale bars = 50 μm; 20x (n=3-4; Student's *t* test).
1007 Results are expressed as mean±SEM. *** *p*<0.001 vs. Control.

1008

1009 **Figure 8. Schematic with mechanisms underlying the peripheral vasculopathy**

1010 **associated with CADASIL.** The vasculopathy associated with CADASIL is also
1011 present in peripheral small vessels where Rho kinase, ER stress and impaired eNOS
1012 activation and redox-regulated sGC/cGMP signalling may be important. We define new
1013 molecular mechanisms underlying the vasculopathy of CADASIL and bring new
1014 insights for novel and attractive therapeutic targets in CADASIL.